Triapine plus radiation for recurrent brain tumors
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a recurrent brain tumor (like glioblastoma, astrocytoma, or midline glioma) that has come back after treatment.
- Your tumor is 6 cm (about 2.4 inches) or smaller.
- It has been at least 6 months since your last radiation treatment to the brain (or you have a new tumor outside the original radiation area, confirmed by biopsy or clear scan changes).
- You are 18 years or older.
- Your overall health is fair (able to do light activities, like walking or light housework).
- Your blood counts, kidney and liver function are within safe limits, and you are not pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, triapine and temozolomide, for people whose glioblastoma has come back after initial treatment. The goal is to see if this combination can help control the tumor.
This trial tests combining two drugs, actimab-A and cemiplimab, for people whose glioblastoma has come back after prior treatment. The goal is to see if this combination can improve outcomes.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
This trial tests a combination of two drugs—APG-157 (an oral plant-based medicine) and bevacizumab (Avastin)—for people with recurrent high-grade brain tumors that have already been treated with standard therapies. The goal is to see if adding APG-157 can help control the tumor better.
Hear when a new Astrocytoma, IDH-Mutant, Grade 2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.